- StudyBlue
- Georgia
- Emory University
- Graduate Nursing
- Graduate Nursing 554
- Ura
- COPD and Asthma
COPD and Asthma
Graduate Nursing 554 with Ura at Emory University
About this deck
Textbook:
CURRENT Medical Diagnosis and Treatment 2012, Fifty-First Edition (LANGE CURRENT Series)Created: 2011-11-13
Size: 33 flashcards
Views: 7
About StudyBlue
Kathy
Sign up (free) to study this.
Disease defined by airflow limitation that is…
-Progressive
-Not fully reversible
-Associated with inflammatory response to noxious agent
-May or may not have emphysema
-Varies greatly from one individual to another
Chronic cough/sputum for 3 months, 2 yrs consecutive
-Pathologically different from emphysema
-R/O other causes for chronic cou
Irreversible increase in air spaces distal to terminal bronchioles, wall destruction
-May or may not have elements of chronic bronchitis
-No Fibrosis
an anatomical description characterized by weakening and permanent enlargement of the airspaces distal to the terminal bronchioles and destruction of the alveolar walls
smoking- primary cause of cb and emphysema
Indoor/Outdoor Pollution
-Occupational
-Perinatal Lung Development
-Socioeconomic Status
-Recurrent Respiratory Illness
-Gender
-Airway Hyperreactivity/Asthma
-Diet
-Genes (α one antitrypsin def)
submucosal gland enlargement and goblet cell hyperplasia lead to overproduction of mucous
Bronchial wall edema
These 2 factors together narrow airwayand increase airway resistance
loss of elastic recoil/ loss of alveolar capillary surface area
Loss of Elastic Recoil
Loss of Cap-Alv SA
leads to increase compliance, increase airway resistance, decrease exp flow rates, hyperinflation
VQ mismatch->hypoxia->pulm vasc comstriction->pulm htn
centrilobular- caused by smoking, Proximal portion terminal bronchiole affected, upper lobe prominence
Panlobular-bronchioles and airsacs affected, has lower lobe prominence, alpha 1 antitrypsin def.
Sputum Production
Dyspnea (Exertional typically)
Fifth decade of Life
Recurrent Respiratory Infections
Thin (severe)
-Pursed Lip breathing (severe)
-Central Cyanosis
-Odor
-Distress? Watch them walk, talk etc….observe
-Depression? Anxiety
-Co-morbidities
-PMH
Assess for presence of heart failure, resp illnesses, GERD, MI, Osteoporosis, Diabetes, Lung Cancer
-Assess for previous history of exacerbations, familial history, smoking history etc
Increase A/P diameter (barrel)
-Tachypnea
-Accessory Muscles, Hoover’s Sign
-Increased resonance to percussion
-Expiratory wheezing
-Decreased breath sounds
Distant heart sounds (listen over xiphoid)
-Check neck veins
α1 Anti-Trypsin Deficiency:
-<45yrs, caucasian, family history….test everyone?>> ATS says yes
-Serum concentration < 15-20% of norm = highly suggestive
ABG: (not sensitive)
-Hypoxemia?
-Compensated respiratory acidosis
-Check if O2 Sat <92% on RA
Hematocrit:
-May be elevated above normal with chronic hypoxemia
Non-diagnostic
-Flattened Diaphragms
-Enlarged Retrosternal Air Space
-Hyperlucency
-Bullous disease?
-Long and Narrow Heart
Chest CT (HRCT):
-Not part of diagnostics > want you to know what to look for
if you have it
-Location of abnormalities (upper lobes vs lower lobes)
Spirometry is the best way to diagnose COPD and to monitor its progression and health care workers to care for COPD patients should have assess to spirometry
A diagnosis of COPD should be considered in any patient who has cough, sputum production, or dyspnea and/or a history of exposure to risk factors. The diagnosis is confirmed by spirometry.
FVC : Forced Vital Capacity
Total volume of air that can be forcibly exhaled in one breath
FEV1 : Forced Expiratory Volume (1st second)
Volume of air expired in first second of forced exhalation
FEV1/FVC Ratio :
Fraction of air exhaled in the first second to total exhalation volume
VC : Vital Capacity
Maximal volume of air that can be inhaled and exhaled in one breath
TLC : Total Lung Capacity
Vital Capacity + Residual Volume
Stage II: Moderate FEV1/FVC < 0.70 50% < FEV1 < 80% predicted
Stage III: Severe FEV1/FVC < 0.70 30% < FEV1 < 50% predicted
Stage IV: Very Severe FEV1/FVC < 0.70 FEV1 < 30% predicted or FEV1 < 50% predicted
plus chronic respiratory failure
B - Body Mass Index
O - Obstruction
D - Dyspnea
E – Exercise
Higher the score = Higher Mortality Risk
BODE score 0-10
Control stable COPD
Observe, assess and monitor disease
Prevent exacerbations
Decrease risk factors
Anticholinergics
Beta-agonists
Methylxanthines
Combination bronchodilators may have sustained effect
-LA bronchodilator treatment more effective and convenient
-Inhaled is preferred route except for methylxanthines
-Combo SABA & Anticholinergic =
Fenoterol Ipratropium & Albuterol Ipratropium
Blocks acetylcholine receptors M3 - bronchodilation
- LA Tiotropium bronchodilating effects longer than SABA, up to 24hrs
-Improves symptoms & FEV 1 acutely
-Common side effect dry mouth
-SA-Ipratropium Bromide, LA- Tiotropium
B2 adrenergic agonists – relaxes airway smooth muscles and
antagonizes bronchoconstriction
-SA-Albuterol, Levobuterol, LA-Salmeterol, Formoterol
-Side Effects: Tachycardia (less tachyphylaxis than we think), Tremors
Methylxanthines
Non-selective Phosphodiesterase inhibitors? Inc exp flow rate?
-Theophylline, Aminophylline
-High risk for toxicity and drug, food interactions, levels
Not inhaled- theophylline and aminophylline
-In addition to B2-Agonist more effective than alone
-Reduces exacerbations & improve symptoms
-Not been shown to alter natural history of disease
-Long term safety still not known
-Shown to decrease BMD long term, fracture risk?
-Can cause oral candidiasis
-Beclomethasone, Budesonide, Fluticasone, Triamcinolone
-Combo LABA/ICS = Formoterol/Budesonide,
Salmeterol/Fluticasone
Stage 1- SA bronchodilator as needed
Stage 2: add LA bronchodilator and pulm rehab
Stage 3: add inhaled glucocorticoid if COPD exacerbations
Stage 4: add O2 if resp failur and consider surgical options
Goal to preserve vital organ function
-Only non-pharmacologic treatment that reduces mortality
-Must have room air PaO2 ≤ 55 mmHg or O2Sat ≤ 88%
-If Pulm Htn, Peripheral edema, Polycthemia and PaO2 55-60 or
O2Sat ≤ 88%.
-Titrate flow to keep Sat 90% or above
-Mortality benefit for > 15hrs/day of oxygen therapy
-Also for exertional and nocturnal hypoxemia
-Infection of tracheobronchial tree
-Air pollution
-Up to 1/3 unknown etiology…? Evidence of disease
progression
Antibiotic Therapy
-Inhaled Bronchodilators (w/wo anticholinergics)
-Oral Glucocorticoids (Oral Prednisone, Methylpred)
-Supplemental O2
-ABG, CXR, CBC
Mild- oral Beta Lactams, Tetra, Bactrim, Macrolides, Cephalosporins
Moderate- oral or IV Beta Lactams, Cephalosporins, or fluoroquinolone
Severe- Fluroquinolone Or Beta Lactam (with Pseudom coverage)
Noninvasive postive pressure ventilation vs ventilator
-Variable recurrent symptoms
-Airway obstruction (Reversible)
-Inflammation (Cellular component)
-Bronchial Hyperresponsiveness
Cellular component = mast cells, eosinophils, T-lymphocytes, macrophages and neutrophils
Ethnicity
Genetic Predisposition
Airway Hyperresponsive
Atopy- allergies
Gender
I/O Allergens
Occupational
Passive Smoking
Respiratory Infection
Obesity
Viral ?
Allergens
URI-viral
Exercise
Cold Air
Sulfur Dioxide
Meds
Stress
Irritants
Inflammation >>> Chronic Repair >>> Eventual Irreversible Narrowing of the Airway in severe patients
Bronchoconstriction + Airway Edema + Vascular congestion + Luminal Mucous >>>
-Airflow Limitation
-Decrease FEV1 and FEV1/FVC ratio
-Decrease peak expiratory flow (PEF)
-Increased Airway Resistance
About this deck
Textbook:
CURRENT Medical Diagnosis and Treatment 2012, Fifty-First Edition (LANGE CURRENT Series)Created: 2011-11-13
Size: 33 flashcards
Views: 7
About StudyBlue
Kathy